This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics' Partner Alcon Launches JETREAA® For The Treatment Of Symptomatic Vitreomacular Adhesion In Canada

LEUVEN, Belgium, November 20, 2013 /PRNewswire/ --

Canada is the first market launch for JETREA ®   outside the US and Europe

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. Canada is the first market where JETREA® has been launched outside the US and Europe.

Symptomatic VMA is estimated to affect up to 15,000 people in Canada each year [ 1 ]. Health Canada approved JETREA ® on August 13, 2013 following priority review.

Alcon, a division of Novartis, acquired the rights to commercialize JETREA ® outside the United States in March 2012. It launched the drug in the UK, its first European market, in April, followed by launches in Germany, Denmark, Finland, Norway and Sweden.

ThromboGenics is commercializing the drug in the US and launched JETREA ® in the US in mid-January 2013 where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).

Dr Patrik De Haes, CEO of ThromboGenics, says:    " The launch of JETREA ®   in Canada, the first market outside the US and Europe, is an another important step in the global roll out of this innovative new drug for the treatment of symptomatic VMA. This is a condition where early pharmacological treatment is being seen as increasingly important in potentially preventing patients '  loss of visual acuity which negatively impacts on their ability to carry out everyday tasks. We are looking forward to working with Alcon as it continues to roll out  JETREA ®   in other European and Rest of the World markets. "   

JETREA ® contains the active substance ocriplasmin. It is administered through a one-time, single intravitreal injection to treat adults with symptomatic VMA.

Symptomatic VMA is an age-related progressive, sight-threatening condition. It is caused by the vitreous having an abnormally strong attachment to the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs